- Home
- ADGM vs SEPN Comparison
ADGM vs SEPN Comparison
Compare ADGM & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADGM
- SEPN
- Stock Information
- Founded
- ADGM 2011
- SEPN 2022
- Country
- ADGM United States
- SEPN United States
- Employees
- ADGM N/A
- SEPN N/A
- Industry
- ADGM
- SEPN
- Sector
- ADGM
- SEPN
- Exchange
- ADGM NYSE
- SEPN NYSE
- Market Cap
- ADGM 19.7M
- SEPN 453.2M
- IPO Year
- ADGM N/A
- SEPN 2024
- Fundamental
- Price
- ADGM $1.42
- SEPN $11.67
- Analyst Decision
- ADGM
- SEPN Strong Buy
- Analyst Count
- ADGM 0
- SEPN 5
- Target Price
- ADGM N/A
- SEPN $26.75
- AVG Volume (30 Days)
- ADGM 42.7K
- SEPN 434.7K
- Earning Date
- ADGM 08-25-2025
- SEPN 08-15-2025
- Dividend Yield
- ADGM N/A
- SEPN N/A
- EPS Growth
- ADGM N/A
- SEPN N/A
- EPS
- ADGM N/A
- SEPN N/A
- Revenue
- ADGM $576,000.00
- SEPN $977,000.00
- Revenue This Year
- ADGM N/A
- SEPN $3,429.67
- Revenue Next Year
- ADGM N/A
- SEPN N/A
- P/E Ratio
- ADGM N/A
- SEPN N/A
- Revenue Growth
- ADGM 116.54
- SEPN 108.76
- 52 Week Low
- ADGM $0.63
- SEPN $4.17
- 52 Week High
- ADGM $9.34
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- ADGM N/A
- SEPN N/A
- Support Level
- ADGM N/A
- SEPN N/A
- Resistance Level
- ADGM N/A
- SEPN N/A
- Average True Range (ATR)
- ADGM 0.00
- SEPN 0.00
- MACD
- ADGM 0.00
- SEPN 0.00
- Stochastic Oscillator
- ADGM 0.00
- SEPN 0.00
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.